LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Vanda Pharmaceuticals Inc

Uždarymo kaina

4.78 -0.83

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.75

Max

4.94

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-25M

-29M

Pardavimai

-3.1M

50M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-58.94

Darbuotojai

368

EBITDA

-23M

-31M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+242.32% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-30

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-4.2M

263M

Ankstesnė atidarymo kaina

5.61

Ankstesnė uždarymo kaina

4.78

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Vanda Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-27 20:51; UTC

Uždarbis

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025-06-27 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-27 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-06-27 20:48; UTC

Rinkos pokalbiai

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

2025-06-27 20:46; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-27 20:46; UTC

Rinkos pokalbiai

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

2025-06-27 19:31; UTC

Rinkos pokalbiai

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

2025-06-27 19:19; UTC

Rinkos pokalbiai

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

2025-06-27 19:16; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025-06-27 18:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-27 18:42; UTC

Rinkos pokalbiai

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

2025-06-27 18:39; UTC

Rinkos pokalbiai
Uždarbis

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

2025-06-27 18:29; UTC

Rinkos pokalbiai

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

2025-06-27 18:18; UTC

Rinkos pokalbiai

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

2025-06-27 18:16; UTC

Rinkos pokalbiai

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

2025-06-27 17:16; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

2025-06-27 17:08; UTC

Uždarbis

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

2025-06-27 16:52; UTC

Įsigijimai, susijungimai, perėmimai

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

2025-06-27 16:22; UTC

Uždarbis

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025-06-27 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-06-27 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-27 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-27 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-27 15:59; UTC

Rinkos pokalbiai

Gold Futures Slump on Improving Risk Appetite -- Market Talk

2025-06-27 15:56; UTC

Rinkos pokalbiai

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Akcijų palyginimas

Kainos pokytis

Vanda Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

242.32% į viršų

12 mėnesių prognozė

Vidutinis 16.5 USD  242.32%

Aukščiausias 20 USD

Žemiausias 13 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Vanda Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

4.22 / 4.44Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.